219 related articles for article (PubMed ID: 22292088)
1. Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses.
Nguyen JT; Smee DF; Barnard DL; Julander JG; Gross M; de Jong MD; Went GT
PLoS One; 2012; 7(1):e31006. PubMed ID: 22292088
[TBL] [Abstract][Full Text] [Related]
2. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice.
Smee DF; Hurst BL; Wong MH; Bailey KW; Morrey JD
Antimicrob Agents Chemother; 2009 May; 53(5):2120-8. PubMed ID: 19273672
[TBL] [Abstract][Full Text] [Related]
3. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro.
Nguyen JT; Hoopes JD; Le MH; Smee DF; Patick AK; Faix DJ; Blair PJ; de Jong MD; Prichard MN; Went GT
PLoS One; 2010 Feb; 5(2):e9332. PubMed ID: 20179772
[TBL] [Abstract][Full Text] [Related]
4. Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus.
Hoopes JD; Driebe EM; Kelley E; Engelthaler DM; Keim PS; Perelson AS; Rong L; Went GT; Nguyen JT
PLoS One; 2011; 6(12):e29778. PubMed ID: 22220216
[TBL] [Abstract][Full Text] [Related]
5. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.
Ilyushina NA; Hoffmann E; Salomon R; Webster RG; Govorkova EA
Antivir Ther; 2007; 12(3):363-70. PubMed ID: 17591026
[TBL] [Abstract][Full Text] [Related]
6. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice.
Ilyushina NA; Hay A; Yilmaz N; Boon AC; Webster RG; Govorkova EA
Antimicrob Agents Chemother; 2008 Nov; 52(11):3889-97. PubMed ID: 18725448
[TBL] [Abstract][Full Text] [Related]
7. Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation.
Kim WY; Young Suh G; Huh JW; Kim SH; Kim MJ; Kim YS; Kim HR; Ryu YJ; Han MS; Ko YG; Chon GR; Lee KH; Choi SH; Hong SB;
Antimicrob Agents Chemother; 2011 Dec; 55(12):5703-9. PubMed ID: 21968371
[TBL] [Abstract][Full Text] [Related]
8. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro.
Nguyen JT; Hoopes JD; Smee DF; Prichard MN; Driebe EM; Engelthaler DM; Le MH; Keim PS; Spence RP; Went GT
Antimicrob Agents Chemother; 2009 Oct; 53(10):4115-26. PubMed ID: 19620324
[TBL] [Abstract][Full Text] [Related]
9. Low dose oral combination chemoprophylaxis with oseltamivir and amantadine for influenza A virus infections in mice.
Masihi KN; Schweiger B; Finsterbusch T; Hengel H
J Chemother; 2007 Jun; 19(3):295-303. PubMed ID: 17594925
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics.
Seo S; Englund JA; Nguyen JT; Pukrittayakamee S; Lindegardh N; Tarning J; Tambyah PA; Renaud C; Went GT; de Jong MD; Boeckh MJ
Antivir Ther; 2013; 18(3):377-86. PubMed ID: 23264438
[TBL] [Abstract][Full Text] [Related]
11. Treatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agents.
Smee DF; Julander JG; Tarbet EB; Gross M; Nguyen J
Antiviral Res; 2012 Oct; 96(1):13-20. PubMed ID: 22809862
[TBL] [Abstract][Full Text] [Related]
12. Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses.
Smee DF; Wong MH; Bailey KW; Sidwell RW
Antivir Chem Chemother; 2006; 17(4):185-92. PubMed ID: 17066897
[TBL] [Abstract][Full Text] [Related]
13. The combination of ribavirin and ozeltamivir effectively inhibits reproduction of influenza A virus resistant to rimantadine (amantadine) in vitro and in vivo.
Deryabin PG; Galegov GA; Konstantinova ID; Muzyka IS; Miroshnikov AI; L'vov DK
Dokl Biochem Biophys; 2014 Mar; 455(1):80-3. PubMed ID: 24795106
[No Abstract] [Full Text] [Related]
14. [Antiviral etiotropic chemicals: efficacy against influenza A viruses A subtype H5N1].
Leneva IA; Shuster AM
Vopr Virusol; 2006; 51(5):4-7. PubMed ID: 17087058
[TBL] [Abstract][Full Text] [Related]
15. Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial.
Beigel JH; Bao Y; Beeler J; Manosuthi W; Slandzicki A; Dar SM; Panuto J; Beasley RL; Perez-Patrigeon S; Suwanpimolkul G; Losso MH; McClure N; Bozzolo DR; Myers C; Holley HP; Hoopes J; Lane HC; Hughes MD; Davey RT;
Lancet Infect Dis; 2017 Dec; 17(12):1255-1265. PubMed ID: 28958678
[TBL] [Abstract][Full Text] [Related]
16. Simvastatin and oseltamivir combination therapy does not improve the effectiveness of oseltamivir alone following highly pathogenic avian H5N1 influenza virus infection in mice.
Belser JA; Szretter KJ; Katz JM; Tumpey TM
Virology; 2013 Apr; 439(1):42-6. PubMed ID: 23453580
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections.
Kumaki Y; Day CW; Smee DF; Morrey JD; Barnard DL
Antiviral Res; 2011 Nov; 92(2):329-40. PubMed ID: 21925541
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses.
Kiso M; Kubo S; Ozawa M; Le QM; Nidom CA; Yamashita M; Kawaoka Y
PLoS Pathog; 2010 Feb; 6(2):e1000786. PubMed ID: 20195462
[TBL] [Abstract][Full Text] [Related]
19. Rational design of a deuterium-containing M2-S31N channel blocker UAWJ280 with
Cáceres CJ; Hu Y; Cárdenas-García S; Wu X; Tan H; Carnaccini S; Gay LC; Geiger G; Ma C; Zhang QY; Rajao D; Perez DR; Wang J
Emerg Microbes Infect; 2021 Dec; 10(1):1832-1848. PubMed ID: 34427541
[TBL] [Abstract][Full Text] [Related]
20. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice.
Smee DF; Hurst BL; Wong MH; Bailey KW; Tarbet EB; Morrey JD; Furuta Y
Antimicrob Agents Chemother; 2010 Jan; 54(1):126-33. PubMed ID: 19901093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
